Black Diamond Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.27M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey...